Show simple item record

dc.contributor.authorHerrmann, Eva
dc.contributor.authorKarayalcin, Selim
dc.contributor.authorFlisiak, Robert
dc.contributor.authorvan 't Veen, Annemarie
dc.contributor.authorde Man, Robert A.
dc.contributor.authorSchalm, Solko W.
dc.contributor.authorJanssen, Harry L. A.
dc.contributor.authorHaagmans, Bart L.
dc.contributor.authorCakaloglu, Yilmaz
dc.contributor.authorter Borg, Martijn J.
dc.contributor.authorHansen, Bettina E.
dc.contributor.authorZeuzem, Stefan
dc.date.accessioned2021-03-04T08:45:06Z
dc.date.available2021-03-04T08:45:06Z
dc.date.issued2007
dc.identifier.citationter Borg M. J. , Hansen B. E. , Herrmann E., Zeuzem S., Cakaloglu Y., Karayalcin S., Flisiak R., van 't Veen A., de Man R. A. , Schalm S. W. , et al., "Modelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B", ANTIVIRAL THERAPY, cilt.12, sa.8, ss.1285-1294, 2007
dc.identifier.issn1359-6535
dc.identifier.otherav_64d4247f-903c-4759-bbc5-0df264d7a8ac
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/70140
dc.description.abstractBackground: Pegylated interferon alpha 2b (PEG-IFN-alpha 2b) is effective for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B, although its mechanism of action remains unclear. HBeAg loss is achieved in 36% of patients after one year of PEG-IFN-a2b treatment and combination therapy with lamivudine is not superior to PEG-IFN-alpha 2b monotherapy.
dc.language.isoeng
dc.subjectTemel Eczacılık Bilimleri
dc.subjectBULAŞICI HASTALIKLAR
dc.subjectİmmünoloji
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectVİROLOJİ
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectMikrobiyoloji ve Klinik Mikrobiyoloji
dc.subjectViroloji
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.titleModelling of early viral kinetics and pegylated interferon-alpha 2b pharmacokinetics in patients with HBeAg-positive chronic hepatitis B
dc.typeMakale
dc.relation.journalANTIVIRAL THERAPY
dc.contributor.departmentErasmus University Rotterdam , ,
dc.identifier.volume12
dc.identifier.issue8
dc.identifier.startpage1285
dc.identifier.endpage1294
dc.contributor.firstauthorID181564


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record